scholarly journals Erratum to: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections

2020 ◽  
Vol 76 (1) ◽  
pp. 281-281
Author(s):  
Adam G Stewart ◽  
Patrick N A Harris ◽  
Andrew Henderson ◽  
Mark A Schembri ◽  
David L Paterson
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Oral Cephalosporin ◽  
Tract Infections ◽  
Lactamase Inhibitor

scholarly journals Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections

Medicine ◽  
2020 ◽  
Vol 99 (19) ◽  
pp. e19960
Author(s):  
Li-Chin Lu ◽  
Chih-Cheng Lai ◽  
Shen-Peng Chang ◽  
Shao-Huan Lan ◽  
Shun-Hsing Hung ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Tract Infections ◽  
Lactamase Inhibitor

Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections

2020 ◽  
Vol 75 (9) ◽  
pp. 2384-2393 ◽  
Author(s):  
Adam G Stewart ◽  
Patrick N A Harris ◽  
Andrew Henderson ◽  
Mark A Schembri ◽  
David L Paterson
Keyword(s):  
Urinary Tract ◽  
Clinical Success ◽  
Treatment Options ◽  
Vitro Activity ◽  
Cross Resistance ◽  
In Vitro Activity ◽  
Oral Cephalosporin ◽  
Tract Infections ◽  
Lactamase Inhibitor

Abstract ESBL-producing Enterobacteriaceae as uropathogens have given rise to a sizeable amount of global morbidity. Community and hospital surveillance studies continue to report increasing proportions of these organisms as causes of urinary tract infection (UTI). Due to limited treatment options and the presence of cross-resistance amongst oral antibiotics of different classes, patients often require IV therapy, thereby increasing healthcare costs and reducing the effectiveness of delivering healthcare. Oral cephalosporin antibiotics are well known for their ability to achieve high urinary concentrations, in addition to achieving clinical success for treatment of uncomplicated UTI with a drug-susceptible pathogen. Novel cephalosporin/β-lactamase inhibitor combinations have been developed and demonstrate good in vitro activity against ESBL-producing isolates. A pooled analysis of in vitro activity of existing oral cephalosporin/clavulanate combinations in ESBL-producing Enterobacteriaceae has shown MIC50s of 0.5–1, 0.125–1 and 0.25 mg/L for cefpodoxime, ceftibuten and cefixime, respectively. A novel cyclic boronic acid β-lactamase inhibitor, QPX7728, was able to produce MIC50 values of 0.5 and ≤0.06 mg/L when paired with cefpodoxime and ceftibuten, respectively. Other novel combinations, cefpodoxime/ETX0282 and ceftibuten/VNRX7145, have also demonstrated excellent activity against ESBL producers. Clinical trials are now awaited.

▾Cefuroxime axetil: a new oral cephalosporin

1989 ◽  
Vol 27 (2) ◽  
pp. 5-7
Keyword(s):  
Urinary Tract ◽  
Oral Administration ◽  
Urinary Tract Infections ◽  
Cefuroxime Axetil ◽  
Oral Cephalosporin ◽  
Previous Issue ◽  
Streptococcus Faecalis ◽  
Gram Negative ◽  
Gram Negative Organisms ◽  
Tract Infections

Parenteral cefuroxime (Zinacef - Glaxo) has been available for over 10 years. It is now available for oral administration as cefuroxime axetil (▾Zinnat). Cefuroxime is stable to many β-lactamases and is active against many Gram-positive and Gram-negative organisms. Like most other cephalosporins, it is not active against Streptococcus faecalis, Pseudomonas spp or Bacteroides spp. We compared its activity with other cephalosporins in a previous issue.1 It is being promoted especially for use in chest and urinary tract infections.

90: A Systematic Review of Urinary Tract Infections Following Transposition of Bowel Segments into Urinary Tract

2004 ◽  
Vol 171 (4S) ◽  
pp. 24-24 ◽  
Author(s):  
Nabi Ghulam ◽  
Sze M. Yong ◽  
Eng Ong ◽  
Adrian Grant ◽  
Gladys C. McPherson ◽  
...  
Keyword(s):  
Systematic Review ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Tract Infections ◽  
Bowel Segments
Sign in / Sign up

Export Citation Format

Share Document